Edition:
India

Aslan Pharmaceuticals Ltd (ASLN.OQ)

ASLN.OQ on NASDAQ Stock Exchange Global Market

2.46USD
12:04am IST
Change (% chg)

$-0.29 (-10.55%)
Prev Close
$2.75
Open
$2.67
Day's High
$2.70
Day's Low
$2.43
Volume
173,399
Avg. Vol
218,388
52-wk High
$8.18
52-wk Low
$0.35

Summary

Name Age Since Current Position

Andrew Howden

2019 Chairman of the Board

Carl Firth

2019 Chief Executive Officer, Director

Mark McHale

2011 Chief Operating Officer

Kiran Asarpota

2010 Vice President-Finance

Zhiyi Xie

2019 Chief Medical Officer

Damien Lim

2016 Director

Jun Wu

2016 Director

Robert Hoffman

53 2018 Independent Director

Chin-Feng Sun

2016 Independent Director

Biographies

Name Description

Andrew Howden

Mr. Andrew James Howden has been serving as Chairman of the Board in ASLAN Pharmaceuticals Limited since July 26, 2019. He holds a Bachelor of Science and a Master's degree in Commerce both from University of New South Wales, Australia. He is also Chairman of the Board in First Pharma Pty Ltd. and True Origin Co Pty Ltd., as well as Director in Howden Family Investments Pty Ltd. and JANK Howden Pty Ltd.

Carl Firth

Mr. Carl Firth (also named Yong Fu) has been serving as Chief Executive Officer and Director in ASLAN Pharmaceuticals Limited since July 26, 2019. He holds a Bachelor's degree in Natural Sciences and a Master's degree in Natural Sciences both from University of Cambridge, the United Kingdom, an Executive Master of Business Administration from London Business School, the United Kingdom, and a Ph.D. in Molecular Biology from University of Cambridge, the United Kingdom. He is also Independent Director in Uni-Bio Science Group Limited, Exploit Technologies Pte Ltd. and Hummingbird Biosciences, as well as Director in Kimba Capital Limited, Liberty Park Music Pte Ltd. and other three companies. He is also a Professor of Duke-NUS Graduate Medical School Singapore.

Mark McHale

Mr. Mark McHale has been serving as Chief Operating Officer in ASLAN PHARMACEUTICALS LIMITED since February 7, 2011. He holds a Bachelor's degree in Biology from University of London, the United Kingdom, and a Ph.D. in Molecular Biology from University of East Anglia, the United Kingdom. He is also Director in Match Point Developments Limited and a Shanghai-based company.

Kiran Asarpota

Mr. Kiran Asarpota has been serving as Vice President-Finance in ASLAN PHARMACEUTICALS LIMITED since November 15, 2010. He holds a Bachelor of Business Administration from Oxford Brookes University, the United Kingdom, and an Master of Business Administration from London South Bank University, the United Kingdom.

Zhiyi Xie

Damien Lim

Mr. Damien Chin Hwee Lim (also named Zhenhui Lin) has been serving as Director in ASLAN Pharmaceuticals Limited since April 15, 2016. He holds a Bachelor of Business Administration from University of Houston, the United States. He is also Director in 68 Holdings Pte. Ltd., AFA Management LLC, BioMers Pte. Ltd., BioVeda Capital Pte Ltd., BioVeda Capital Singapore Pte Ltd., BioVeda Fund Pte Ltd., BV Healthcare II Pte. Ltd., Chrysler Jeep Automotive of Singapore Pte Ltd., Clearbridge BSA Pte. Ltd., Excelfin Pte Ltd., ExCL Inc., ExCL (SF) Inc., HRH Merchandise Singapore Pte Ltd., IFC Holdings Pte Ltd., Integrated Food Concepts Pte. Ltd., Ital Auto Pte. Ltd., Karmelitská Hotel s.r.o., Komoco (China) Pte. Ltd., Komoco Car Rentals Pte Ltd., Komoco Holdings Pte Ltd., Komoco Investments Pte Ltd., Komoco Motorcycles Pte. Ltd., Komoco Motors (M) Sdn Bhd, Komoco Motors Pte Ltd., Komoco Properties Pte Ltd., Komoco Trading Pte Ltd., Leisure Ventures Pte Ltd., LV Hotel Investment (West) Pte Ltd., LV Investments (USA) Pte Ltd., LV Resort (Thailand) Pte Ltd., Mach7 Technologies Limited, Mach7 Technologies Pte. Ltd., MBSA Automotive Malaysia Sdn Bhd, Mojo Partners Pte. Ltd., MSC Hotel Investments Coöperatie U.A., Nusantara Jutamas Sdn. Bhd., Presto Television Pte Ltd., Promus Private Limited, Safe Foods Asia Pte. Ltd., Singapore Advanced Biologics Pte. Ltd., The Yamu Club Villa Ltd., The Yamu Limited and Zenith Securities Pte Ltd.

Jun Wu

Jun Wu has been serving as Director in ASLAN PHARMACEUTICALS LIMITED since April 15, 2016. Wu holds a Bachelor's degree in Biology from San Jose State University, the United States, and a Ph.D. from University of California, San Francisco, the United States. Wu is also Director in Alnair Investment, Novoasis Investment Ltd., Optomed Oy, two investment companies, a Suzhou-based company and six Shanghai-based companies, as well as General Manager in other seven Shanghai-based companies.

Robert Hoffman

Chin-Feng Sun

Mr. Chin-Feng Sun (also named Qingfeng Sun) has been serving as Independent Director in ASLAN Pharmaceuticals Limited since April 15, 2016. He holds a Master of Business Administration from University of Michigan, the United States, and a Master's degree in Materials Science from Wayne State University, the United States. He is also Independent Director in TWi Pharmaceuticals, Inc., TAH TONG TEXTILE CO., LTD. and Wonderful Hi-Tech Co., Ltd., Chairman of the Board in FiTek Photonics Corporation, two investment companies and another company, Director in Signax Technology Capital Inc., LYTONE ENTERPRISE, INC., a development company and another investment company, as well as General Manager in SAGA UNITEK VENTURES.